Tags

Type your tag names separated by a space and hit enter

SCH 23390 in the prefrontal cortex enhances the effect of apomorphine on prepulse inhibition of rats.
Neuropharmacology. 2006 Sep; 51(3):438-46.N

Abstract

The aim of this study was to investigate the role of dopaminergic activity in the prefrontal cortex in the regulation of prepulse inhibition (PPI) of acoustic startle. Rats were instrumented with permanent indwelling cannulas into the prefrontal cortex region and tested at least one week after surgery using a randomized sequence, repeated-measures protocol. Doses of apomorphine (0.1 mg/kg subcutaneously, s.c.) and MK-801 (0.03 mg/kg s.c.) were obtained from preliminary dose-response studies. Intracerebral injection of 0.5 microg/side of the dopamine D1 receptor antagonist, SCH 23390, significantly enhanced the disruptive effect of apomorphine on PPI, but had no effect on its own or on startle amplitude or habituation. Furthermore, the effect of SCH 23390 on PPI was not seen with a lower dose (0.2 microg/side) or in combination with the NMDA receptor antagonist, MK-801. These data confirm and extend previous reports on the importance of dopaminergic innervation of the prefrontal cortex in the regulation of PPI. It is suggested that apomorphine treatment directly or indirectly activates dopamine D1 receptors in the prefrontal cortex to inhibit its own action on PPI elsewhere in the brain, presumably in the nucleus accumbens. Antagonism of this inhibitory component by SCH 23390 therefore leads to a larger disruption of PPI.

Authors+Show Affiliations

de Jong IE
Behavioural Neuroscience Laboratory, The Mental Health Research Institute of Victoria, Parkville, Melbourne, Vic. 3052, Australia.
van den Buuse M
No affiliation info available

MeSH

Acoustic StimulationAnalysis of VarianceAnimalsApomorphineBehavior, AnimalBenzazepinesDizocilpine MaleateDopamine AgonistsDopamine AntagonistsDose-Response Relationship, DrugDose-Response Relationship, RadiationDrug SynergismExcitatory Amino Acid AntagonistsMaleNeural InhibitionPrefrontal CortexRatsRats, Sprague-DawleyReflex, Startle

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16740279

Citation

de Jong, Inge E M., and Maarten van den Buuse. "SCH 23390 in the Prefrontal Cortex Enhances the Effect of Apomorphine On Prepulse Inhibition of Rats." Neuropharmacology, vol. 51, no. 3, 2006, pp. 438-46.
de Jong IE, van den Buuse M. SCH 23390 in the prefrontal cortex enhances the effect of apomorphine on prepulse inhibition of rats. Neuropharmacology. 2006;51(3):438-46.
de Jong, I. E., & van den Buuse, M. (2006). SCH 23390 in the prefrontal cortex enhances the effect of apomorphine on prepulse inhibition of rats. Neuropharmacology, 51(3), 438-46.
de Jong IE, van den Buuse M. SCH 23390 in the Prefrontal Cortex Enhances the Effect of Apomorphine On Prepulse Inhibition of Rats. Neuropharmacology. 2006;51(3):438-46. PubMed PMID: 16740279.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SCH 23390 in the prefrontal cortex enhances the effect of apomorphine on prepulse inhibition of rats. AU - de Jong,Inge E M, AU - van den Buuse,Maarten, Y1 - 2006/06/05/ PY - 2006/02/28/received PY - 2006/03/30/revised PY - 2006/04/04/accepted PY - 2006/6/3/pubmed PY - 2006/12/15/medline PY - 2006/6/3/entrez SP - 438 EP - 46 JF - Neuropharmacology JO - Neuropharmacology VL - 51 IS - 3 N2 - The aim of this study was to investigate the role of dopaminergic activity in the prefrontal cortex in the regulation of prepulse inhibition (PPI) of acoustic startle. Rats were instrumented with permanent indwelling cannulas into the prefrontal cortex region and tested at least one week after surgery using a randomized sequence, repeated-measures protocol. Doses of apomorphine (0.1 mg/kg subcutaneously, s.c.) and MK-801 (0.03 mg/kg s.c.) were obtained from preliminary dose-response studies. Intracerebral injection of 0.5 microg/side of the dopamine D1 receptor antagonist, SCH 23390, significantly enhanced the disruptive effect of apomorphine on PPI, but had no effect on its own or on startle amplitude or habituation. Furthermore, the effect of SCH 23390 on PPI was not seen with a lower dose (0.2 microg/side) or in combination with the NMDA receptor antagonist, MK-801. These data confirm and extend previous reports on the importance of dopaminergic innervation of the prefrontal cortex in the regulation of PPI. It is suggested that apomorphine treatment directly or indirectly activates dopamine D1 receptors in the prefrontal cortex to inhibit its own action on PPI elsewhere in the brain, presumably in the nucleus accumbens. Antagonism of this inhibitory component by SCH 23390 therefore leads to a larger disruption of PPI. SN - 0028-3908 UR - https://www.unboundmedicine.com/medline/citation/16740279/SCH_23390_in_the_prefrontal_cortex_enhances_the_effect_of_apomorphine_on_prepulse_inhibition_of_rats_ DB - PRIME DP - Unbound Medicine ER -